AI-Powered Precision Decision-Making for Pancreatic Diseases

Официальное название

A Multicenter Clinical Study on AI-Powered Precision Decision-Making Management for Pancreatic Diseases Using Contrast-Enhanced CT

Обзор

This multicenter clinical trial evaluates an artificial intelligence (AI) system designed to assist in the diagnosis and management of pancreatic diseases. Using contrast-enhanced CT scans, the study compares the AI's recommendations against the decisions of experienced clinicians to verify the system's accuracy and safety in a real-world setting. Patients are categorized into three management groups: Intervention (surgery/treatment), Intensive Surveillance (close monitoring), or Routine Surveillance (standard follow-up). The primary goal is to determine if the AI system can reliably classify patients, reduce the risk of missing malignant lesions, and prevent unnecessary surgeries, thereby improving clinical decision-making for pancreatic conditions.

Подробное описание

MEHTOD： This multicenter clinical trial evaluates the reliability and effectiveness of an AI system for patients with pancreatic diseases in a real-world clinical environment. The study calculates the AI system's classification accuracy using pathological diagnosis (biopsy/surgery results) or long-term follow-up as the "gold standard" for comparison. Additionally, the safety and clinical utility of the management strategies recommended by the AI are assessed by measuring the risk of missing malignant lesions, the rate of unnecessary surgeries for pancreatic diseases, and the level of agreement with traditional clinical decisions.

STUDY DESIGN

All contrast-enhanced CT images from patients with pancreatic diseases are analyzed by the AI system to generate a classification result (Intervention, Intensive Surveillance, or Routine Surveillance). Simultaneously, clinical doctors review the same data and categorize patients into these three groups to determine their actual care plan:

1. INTERVENTION: Patients assessed by doctors as needing "Intervention" are recommended for further surgical evaluation or treatment. 2. INTENSIVE SURVEILLANCE: Patients assessed by doctors as needing "Intensive Surveillance" receive a personalized, high-frequency follow-up plan until the study endpoint. 3. ROUTINE SURVEILLANCE: Patients assessed by doctors as needing "Routine Surveillance" undergo follow-up for at least one year. If abnormalities arise during this period, the patient is transferred to the appropriate "Intervention" or "Intensive Surveillance" protocol.

OUTCOMES： The study compares the performance of the AI system against clinical doctors regarding classification accuracy, the risk of missed diagnoses, unnecessary surgery rates, and decision consistency. These metrics are used to validate the AI system's value, safety, and utility in the clinical management of pancreatic diseases.

Вмешательства

• Диагностический тест Diagnosis by Artificial Intelligence model
  To develop an artificial intelligence-based classification management system for pancreatic diseases, achieving automated and precise classification. Contrast-enhanced CT images from all study subjects will be analyzed by the AI system to generate classification results, categorizing patients into three groups: INTERVENTIOM, INTENSIVE SURVEILLANCE or ROUTINE SURVEILLANCE.

Первичные конечные точки

• Classification accuracy [Срок оценки: From date of contrast-enhanced CT scan to 1 year]

Вторичные конечные точки (3)

• Agreement rate with clinical decisions [Срок оценки: From date of contrast-enhanced CT scan to 1 year]
• Percentage decrease in unnecessary surgical procedures [Срок оценки: From date of contrast-enhanced CT scan to 1 year]
• Malignancy miss rate [Срок оценки: From date of contrast-enhanced CT scan to 1 year]

Критерии участия

Критерии включения

• Clinically suspected pancreatic disease.
• Scheduled to undergo contrast-enhanced CT.
• Signed informed consent form indicating agreement to participate.

Критерии исключения

• History of pancreatic surgery.
• Contraindications to contrast-enhanced CT, including known hypersensitivity to iodinated contrast media or severe renal/hepatic dysfunction.
• Suboptimal image quality affecting diagnosis.
• Concurrent participation in another interventional clinical trial.
• Unsuitability for participation as determined by the investigator, including but not limited to: pregnancy or lactation, severe psychiatric disorders or cognitive impairment, significant comorbidities that may interfere with study results or patient safety.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Когортное

Центры проведения

Китай · 1 центр

• Changhai Hospital — Шанхай

Идентификаторы

NCT: NCT07439757 · Prospective PRISM

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗